Key result
In patients with cancer-associated venous thromboembolism, concomitant use of anti-platelet drugs significantly increased the risk of recurrent symptomatic thromboembolism (HR 7.59).
Why the study?
Many aspects of cancer-associated venous thromboembolism remain unclear, including treatment indications and treatment duration.
Does anticoagulant therapy prevent recurrent thromboembolism and what are the risk factors for recurrence and bleeding in patients with cancer-associated VTE?
Cohort (n=151)
No
Does anticoagulant therapy prevent recurrent thromboembolism and what are the risk factors for recurrence and bleeding in patients with cancer-associated VTE?
In cancer-associated VTE, asymptomatic patients have similar recurrence risks as symptomatic ones and benefit from anticoagulation, with baseline D-dimer ≥3.0 µg/mL being a strong predictor for recurrence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2020) conducted a cohort in Cancer-associated venous thromboembolism (n=151). Direct oral anticoagulants (DOACs) was evaluated on Recurrent symptomatic thromboembolism (concomitant use of anti-platelet drugs) (HR 7.59, 95% CI 1.14-30.80, p=0.039). In patients with cancer-associated venous thromboembolism, concomitant use of anti-platelet drugs significantly increased the risk of recurrent symptomatic thromboembolism (HR 7.59).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: